EU Plans 'Critical Medicines Act' to Secure Supply Chain

The European Union is advancing its 'Critical Medicines Act,' an ambitious legislative effort designed to address persistent shortages of essential pharmaceuticals. The Act aims to bolster the security and sustainability of the region’s drug supply by incentivizing EU-based manufacturing. For global pharmaceutical and life sciences companies, this represents a significant policy shift in one of the world's largest markets. The initiative could reshape supply-chain strategies, requiring companies that rely on non-EU manufacturing to re-evaluate their operations to and within the bloc. The legislation may introduce new procurement preferences for local producers or create other regulatory hurdles for imported medicines. Counsel for affected clients should closely monitor the Act’s development to anticipate specific incentives and requirements, as these will likely influence future investment decisions and alter the competitive landscape for medicines deemed critical to the EU.